The present disclosure generally relates to personal care compositions comprising polyols and methods related thereto.
The desirability of personal care compositions can be influenced by a variety of factors. For example, consumers are likely to desire personal care compositions that exhibit suitable cleaning and lathering characteristics, are non-drying to the skin, and display favorable rheological properties. Additionally, other factors such as environmental temperature can affect the desirability of the personal care composition as fluctuations in temperature can affect the viscosity and/or elasticity of the personal care composition; potentially impacting the consumer's opinion of whether the personal care composition displays favorable rheological properties. Balancing these qualities can be challenging as the choice of surfactant(s) and other substances in the personal composition can affect one or more or more of these factors. Thus, there is a need in the market for personal care compositions that exhibit suitable cleaning and lathering characteristics, are non-drying to the skin, and display favorable rheological properties.
A personal care composition comprising a primary surfactant, a secondary surfactant, and a polyol. The primary surfactant comprises an anionic surfactant not sodium lauryl sulfate or ammonium lauryl sulfate. The secondary surfactant comprises a zwitterionic surfactant, an amphoteric surfactant, a non-ionic surfactant, or a combination thereof. The personal care composition exhibits a tan delta of about 0.30 or more at about 10° C.
A personal care composition comprising: a primary surfactant comprising sodium laureth (3) sulfate; a secondary surfactant comprising a zwitterionic surfactant, an amphoteric surfactant, a non-ionic surfactant, or a combination thereof; a viscosity modifier; and sorbitol comprising from about 0.5% to less than 10% by weight of the personal care composition; wherein the personal care composition exhibits a tan delta of about 0.35 or more at about 10° C. and is substantially free of sodium lauryl sulfate.
This application claims priority to U.S. provisional application No. 61/719,738 filed Oct. 29, 2012, which is incorporated herein by reference.
While the specification concludes with the claims particularly pointing and distinctly claiming the invention, it is believed that the present invention will be better understood from the following description.
The devices, apparatuses, methods, components, and/or compositions of the present invention can include, consist essentially of, or consist of, the components of the present invention as well as other ingredients described herein.
All percentages and ratios used herein are by weight of the total personal care composition and all measurements made are at 25° C., unless otherwise designated.
All measurements used herein are in metric units unless otherwise specified.
“ALS” refers to ammonium lauryl sulfate.
“CAPB” refers to cocamidopropyl betaine.
“SLS” refers to sodium lauryl sulfate.
“SLES” refers to sodium laureth(n) sulfate.
The term “personal care composition” as used herein, refers to compositions intended for topical application to the skin and/or hair.
The phrase “substantially free of” as used herein, unless otherwise specified means that the personal care composition comprises less than about 2%, less than about 1%, and less than about 0.1% of the stated ingredient. The term “free of” as used herein means that the personal care composition comprise 0% of the stated ingredient that is, the ingredient has not been added to the personal care composition. However, these ingredients may incidentally form as a byproduct or a reaction product of the other components of the personal care composition.
“Stable” refers to a personal care composition having a tan delta greater than about 0.30, about 0.31, about 0.32, about 0.33, about 0.34, or about 0.35 at 10° C. as measured by the method described herein, unless otherwise stated.
Personal Care Compositions
The personal care compositions can be rinse-off formulations that can be applied topically to the skin and/or hair and rinsed from the skin and/or hair within minutes with water. The personal care compositions can exhibit a viscosity of from about 1,000 centipoise (cP) to about 1,000,000 cP, about 1,500 centipoise (cP) to about 1,000,000 cP, from about 5,000 centipoise (cP) to about 1,000,000 cP, from about 6,000 centipoise (cP) to about 1,000,000 cP, or from about 8,000 centipoise (cP) to about 1,000,000 cP, at about 25° C. as measured by the method described herein. The personal care compositions can also be used as shaving aids. The personal care compositions can be extrudable or dispensable from a package. The personal care compositions can be in the form of, for example, a liquid, semi-liquid cream, lotion, or gel and can be intended for topical application to the skin and/or hair. Examples of personal care compositions can include, but are not limited to, shampoo, conditioning shampoo, body wash, moisturizing body wash, shower gels, skin cleansers, cleansing milks, hair and body wash, in shower body moisturizer, pet shampoo, shaving preparations, and cleansing compositions used in conjunction with a disposable cleansing cloth.
The desirability of personal care compositions can be influenced by a variety of factors including the amount and types of surfactants present in the personal care composition. Many consumers use personal care compositions because the personal care compositions can remove dirt, sweat, sebum, and other substances from the skin and/or hair. However, in addition to the cleaning properties displayed by the personal care composition, the desirability of the personal care composition can be also influenced by other factors.
For example, the desirability of a personal care composition can vary depending on the type and amount of the surfactants included in a formulation of a personal care composition. In this regard, a consumer may view a personal care composition as unfavorable when the personal care composition includes surfactants that promote the drying of the skin. Additionally, because many consumers equate cleaning efficiency with the level of foam generated upon using a particular personal care composition, consumers may not desire personal care compositions that include surfactants that do not foam to the level desired. Also potentially impacting the consumers' perception of a personal care composition are the rheological properties displayed by the personal care composition. For example, temperature fluctuations may cause changes in the rheological properties of the personal care composition such that the consumer perceives the product as being too thick and/or indispensable. The balancing of the aforementioned factors while concurrently maintaining the cleaning properties of the personal care composition can be a challenging endeavor.
In addition to the above complexities, some consumers desire a thick product. Thick products can be created by increasing the viscosity of a personal care composition. However, viscosity can be linked to the elastic behavior of the personal care composition, so increasing the viscosity can have negative effects on product feel. One such negative effect is the development of a springy or gel-like character which consumers can dislike.
The rheological behavior of a personal care composition can be characterized by its tan delta. Increasing the viscosity of a personal care composition can lower its tan delta to an unacceptable level, giving the personal care composition an undesired gel-like consistency. Thus, a personal care composition's viscosity and tan delta can be balanced to give the consumer a more acceptable product. For example, a personal care composition with a tan delta above about 0.30, above about 0.31, above about 0.32, above about 0.33, above about 0.34, or above about 0.35 at 10° C. may be perceived by a consumer as having sufficient viscosity to flow over the skin, but not too gel-like or otherwise difficult to spread on the skin or dispense from the package. In contrast, a personal care composition with a tan delta below about 0.30 at 10° C. may be perceived as too gel-like and difficult to spread on the skin and dispense from the container. Additionally, a personal care composition with a thickness below 5000 cP at about 25° C. may be perceived as too thin. In contrast, a personal care composition with a thickness above 5000 cP at about 25° C. may be perceived as having sufficient thickness. The personal care compositions can have a tan delta up to about 20.
A personal care composition's tan delta can fluctuate not only with changes in viscosity, but also across temperature. For example, although a personal care composition may have an acceptable tan delta at room temperature (e.g., 25° C.), the tan delta may be too low at lower temperatures such as at about 10° C. In order to have a composition that can be shipped, stored, and used in all seasons, a tan delta of about 0.30 or more measured at about 10° C. is desired.
It has presently been discovered that the inclusion of certain types of surfactants, like sodium lauryl sulfate (SLS) and other non-ethoxylated alkyl sulfates, can negatively affect the tan delta of a personal care composition at low temperature. Without being limited by theory, this is believed to be due, at least in part, to the degree to which the micelles formed by the surfactant in a personal care composition can compact. SLS is a smaller surfactant molecule and tends to allow for more rigid packing of the micelles. It is believed this more rigid packing can lead to instability of the composition at low temperatures resulting in a lower tan delta. Thus, the stability of a personal care composition at low temperatures can be increased by the removal of SLS from a personal care composition.
Surprisingly, it has also been found that the addition of particular polyols to certain personal care compositions that are free, or substantially free, of SLS can enhance the viscosity and/or improve the rheological properties of certain personal care composition. Surprisingly, it has also been found that even levels of polyols less than about 10% or less by weight of the personal care composition can enhance the viscosity and/or improve the rheological properties of certain personal care compositions free or substantially free of non-ethoxylated alkyl sulfates.
The finding that the addition of particular polyols to certain personal care compositions that are free or substantially free of non-ethoxylated alkyl sulfates can enhance the viscosity and/or improve the rheological properties of the personal care composition is surprising, for example, given the unpredictable nature of polyols in personal care compositions. In this regard, the inclusion of high levels of polyols like glycerin in certain personal care compositions containing sulfosuccinic acid monoester surfactants has been shown to potentially lead to the destabilization of certain personal care compositions.
Primary Surfactants
The personal care composition can comprise a primary surfactant that can comprise an anionic surfactant. The primary surfactant can comprise from about 5% to about 10%, from about 6.4% to about 10%, and from about 6.4% to about 8.4% by weight of the personal care composition. The anionic surfactant can be sodium laureth(n) sulfate, hereinafter SLEnS, wherein n defines the average moles of ethoxylation. The anionic surfactant can also be ammonium laureth(n) sulfate, hereinafter ALEnS, wherein n defines the average moles of ethoxylation. For example, n can range from greater than about 0 to about 3, alternatively from about 0.5 to about 2.7, alternatively from about 1.1 to about 2.5, alternatively from greater than about 0 to about 2.5, alternatively from about 1.8 to about 2.2, or alternatively about 2. It is understood that a material such as SLE3S, for example, may comprise a significant amount of molecules which have no ethoxylate, 1 mole ethoxylate, 4 mole ethoxylate, and so on in a distribution which can be broad, narrow or truncated, while still comprising SLE3S wherein the average of the distribution is about 3. It is understood that a material such as SLE2S, for example, may comprise a significant amount of molecules which have no ethoxylate, 1 mole ethoxylate, 4 mole ethoxylate, and so on in a distribution which can be broad, narrow or truncated, while still comprising SLE2S wherein the average of the distribution is about 2. It is understood that a material such as SLE1S, for example, may comprise a significant amount of molecules which have no ethoxylate, 1 mole ethoxylate, 4 mole ethoxylate, and so on in a distribution which can be broad, narrow or truncated, while still comprising SLE2S wherein the average of the distribution is about 1.
The anionic surfactant can also be sodium trideceth(n) sulfate (hereinafter STnS) and/or ammonium trideceth(n) sulfate (hereinafter ATnS), wherein n defines the average moles of ethoxylation. For example, n can range from greater than 0 to 3, alternatively from 0.5 to 2.7, alternatively from 1.1 to 2.5, alternatively from greater than 0 to 2.5, alternatively from 1.8 to 2.2, alternatively about 2. It is understood that a material such as ST2S, for example, may comprise a significant amount of molecules which have no ethoxylate, 1 mole ethoxylate, 3 mole ethoxylate, and so on in a distribution which can be broad, narrow or truncated, while still comprising ST2S wherein the average of the distribution is about 2.
Other anionic surfactants suitable for use in the personal cleansing compositions are the succinates, examples of which include disodium N-octadecylsulfosuccinnate; disodium lauryl sulfosuccinate; diammonium lauryl sulfosuccinate; tetrasodium N-(1,2-dicarboxyethyl)-N-octadecylsulfosuccinnate; diamyl ester of sodium sulfosuccinic acid; dihexyl ester of sodium sulfosuccinic acid; and dioctyl esters of sodium sulfosuccinic acid.
Other examples of anionic surfactants for use in the personal cleansing compositions include sodium lauryl sarcosinate, sodium lauroyl sarcosinate, lauryl sarcosine, cocoyl sarcosine, alkyl phosphate esters, ethoxylated alkyl phosphate esters, and combinations thereof.
Often, SLE1S, SLE2S, and SLE3S are combined with SLS in personal care compositions. Examples of personal care compositions can comprise less than about 2% SLS, alternatively less than about 1% SLS, alternatively less than about 0.5% SLS, alternatively less than about 0.1% SLS, alternatively less than about 0.05% SLS, alternatively between about 0.01% SLS and about 0.05% SLS, alternatively about 0% SLS.
Often, SLE1S, SLE2S, and SLE3S or ALE1S, ALE2S, and ALE3S are combined with ALS in personal care compositions. Examples of personal care compositions can comprise less than about 2% ALS, alternatively less than about 1% ALS, alternatively less than about 0.5% ALS, alternatively less than about 0.1% ALS, alternatively less than about 0.05% ALS, alternatively between about 0.01% ALS and about 0.05% ALS, alternatively about 0% ALS.
Cosurfactants
The personal care compositions can also comprise a cosurfactant. Cosurfactants can comprise from 0.1% to 20%, from about 2% to about 10%, or from about 2% to about 5% by weight of the personal care composition. Cosurfactants may also comprise more than 20% by weight of the personal care composition. Cosurfactants can comprise amphoteric surfactants, zwitterionic surfactants, non-ionic surfactants, and mixtures thereof.
Examples of amphoteric/zwitterionic surfactants are betaine surfactants. Examples of betaine surfactants useful herein include the high alkyl betaines such as coco dimethyl carboxymethyl betaine, lauryl dimethyl carboxymethyl betaine, lauryl dimethyl alpha-carboxyethyl betaine, cetyl dimethyl carboxymethyl betaine, lauryl bis-(2-hydroxy-ethyl) carboxy methyl betaine, stearyl bis-(2-hydroxy-propyl) carboxymethyl betaine, oleyl dimethyl gamma-carboxypropyl betaine, lauryl bis-(2-hydroxypropyl) alpha-carboxyethyl betaine, etc. Other betaines are the sulfobetaines which may be represented by coco dimethyl sulfopropyl betaine, stearyl dimethyl sulfopropyl betaine, lauryl dimethyl sulfoethyl betaine, lauryl bis-(2-hydroxy-ethyl) sulfopropyl betaine and the like; amido betaines and amidosulfobetaines, wherein an RCONH(CH2)x radical is attached to the nitrogen atoms of the betaine are also useful in this invention. A preferred betaine is cocamidopropyl betaine.
Other useful surfactants include the amphoacetates such as sodium laurylamphoacetate and nonionic surfactants like, for example, glucosides such as decyl glucosides, monoglycerides such as glyceryl monolaurate, alkanolamides such as cocomonoethanolamide, and glyceryl ethers such as PEG-80 glyceryl cocoate.
Water
The liquid personal cleansing compositions of the present invention can also contain from about 20% to about 95%, from about 40% to about 90%, from about 60% to about 90%, and from about 70% to about 90% water by weight of the compositions.
Modifiers
The personal care compositions can further comprise a viscosity modifier for modifying the viscosity of the personal care composition. Such concentrations can range, for example, from about 0.1% to about 10%, from about 0.3% to about 5.0%, or from 0.5% to 3% by weight of the personal care compositions.
Non limiting examples of viscosity modifiers useful herein include inorganic salts. Examples of inorganic salts useful herein magnesium nitrate, trimagnesium phosphate, calcium chloride, sodium carbonate, sodium chloride, sodium aluminum sulfate, disodium phosphate, sodium polymetaphosphate, sodium magnesium succinate, sodium sulfate, sodium tripolyphosphate, aluminum sulfate, aluminum chloride, aluminum chlorohydrate, aluminum-zirconium trichlorohydrate, aluminum-zirconium trichlorohydrate glycine complex, zinc sulfate, ammonium chloride, ammonium phosphate, ammonium sulfate, calcium acetate, calcium nitrate, calcium phosphate, calcium sulfate, ferric sulfate, magnesium chloride, magnesium sulfate, alkyl ether sulfate, mixtures thereof, and the like.
Viscosity modifiers can also include polymers. Non limiting examples of polymers include cellulose derivatives and modified cellulose polymers such as methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, nitro cellulose, sodium cellulose sulfate, sodium carboxymethyl cellulose, crystalline cellulose, cellulose powder, polyvinylpyrrolidone, polyvinyl alcohol, guar gum, hydroxypropyl guar gum, xanthan gum, arabia gum, tragacanth, galactan, carob gum, guar gum, karaya gum, carrageenan, pectin, agar, quince seed (Cydonia oblonga Mill), starch (rice, corn, potato, wheat), algae colloids (algae extract), microbiological polymers such as dextran, succinoglucan, pulleran, starch-based polymers such as carboxymethyl starch, methylhydroxypropyl starch, alginic acid-based polymers such as sodium alginate, alginic acid propylene glycol esters, acrylate polymers such as sodium polyacrylate, polyethylacrylate, polyacrylamide, polyethyleneimine, and inorganic water soluble material such as bentonite, aluminum magnesium silicate, laponite, hectonite, and anhydrous silicic acid.
Polyol
The personal care compositions can further comprise polyols. Such concentrations can range, for example, from about 0.1% to about 10%, from about 0.3% to about 5.0%, or from 0.5% to 3% by weight of the personal care compositions.
Non limiting examples of polyols useful herein include glycerin, sorbitol, propylene glycol, butylene glycol, hexylene glycol, ethoxylated glucose, 1,2-hexane diol, hexanetriol, dipropylene glycol, trehalose, diglycerin, maltitol, maltose, glucose, fructose, sodium chondroitin sulfate, sodium hyaluronate, sodium adenosin phosphate, sodium lactate, pyrrolidone carbonate, glucosamine, cyclodextrin, and mixtures thereof.
Other Optional Ingredients
The personal care compositions can also include other personal care adjunct ingredients that may modify the physical, chemical, cosmetic or aesthetic characteristics of the compositions or serve as “active” components when deposited on the skin. Non limiting examples of such adjunct ingredients include preservatives (e.g., propyl paraben), deodorants, antimicrobials, fragrances, deodorant perfumes, coloring agents or dyes, thickeners, sensates, sunscreens, surfactants or emulsifiers, gellants or other suspending agents, pH modifiers, co-solvents or other additional solvents, emollients, pharmaceutical actives, vitamins, and combinations thereof. Other non-limiting examples of adjunct ingredients include: enzymes, abrasives, skin exfoliating agents, absorbents, aesthetic components such as fragrances, pigments, colorings/colorants, essential oils, skin sensates, astringents, etc. (e.g., clove oil, menthol, camphor, eucalyptus oil, eugenol, menthyl lactate, witch hazel distillate), anti-acne agents (e.g., resorcinol, sulfur, salicylic acid, erythromycin, zinc, etc.), anti-caking agents, antifoaming agents, additional antimicrobial agents (e.g., iodopropyl butylcarbamate), antioxidants, binders, biological additives, buffering agents, bulking agents, chelating agents, chemical additives, colorants, cosmetic astringents, cosmetic biocides, denaturants, drug astringents, external analgesics, film formers or materials, e.g., polymers, for aiding the film-forming properties and substantivity of the composition (e.g., copolymer of eicosene and vinyl pyrrolidone), humectants, opacifying agents, pH adjusters, propellants, reducing agents, sequestrants, skin bleaching agents (or lightening agents) (e.g., hydroquinone, kojic acid, ascorbic acid, magnesium ascorbyl phosphate, ascorbyl glucosamine), skin-conditioning agents (humectants, including miscellaneous and occlusive), skin soothing and/or healing agents (e.g., panthenol and derivatives (e.g., ethyl panthenol), aloe vera, pantothenic acid and its derivatives, allantoin, bisabolol, and dipotassium glycyrrhizinate), skin treating agents, including agents for preventing, retarding, arresting, and/or reversing skin wrinkles (e.g., alpha-hydroxy acids such as lactic acid and glycolic acid and beta-hydroxy acids such as salicylic acid), thickeners, hydrocolloids, particular zeolites, and vitamins and derivatives thereof (e.g. tocopherol, tocopherol acetate, beta carotene, retinoic acid, retinol, retinoids, retinyl palmitate, niacin, niacinamide, panthenol, and the like).
Test Methods
The viscosity of the personal care composition can be measured using a digital Brookfield Viscometer (model RVDVII) with a CPE-41 spindle with temperature control. The viscosity is measured at 25° C., with a 1 mm gap (distance between the rotating spindle and the wall of the RVDVII), at a shear rate of 1 RPM (rotations per minute). Each measurement is taken for a period of two minutes to allow for the collection of enough data points to determine the average viscosity of the product (i.e. the spindle rotates at 1 rpm for 2 minutes).
The ratio of G″ to G′ (i.e. G″÷G′) is referred to as the tan delta. To measure the viscous modulus (G″) and elastic modulus (G′) of a personal care composition, an Advanced Rheometer, AR G2 Rheometer (TA Instruments, Del., USA) equipped with a 1 degree cone upper geometry having a diameter of 40 mm and a flat plate lower geometry equipped with a peltier heating/cooling mechanism to control temperature is used. Measurements are conducted by placing approximately 1 gram of the personal care composition onto the lower test geometry and lowering the upper geometry to the desired gap of about 27 micrometers, wiping away any excess of the personal care composition to create an even surface around the edges of the upper and lower geometries. The test is conducted over a frequency range of 0.01 to 100 radians per second, collecting 10 data points per decade, using a constant oscillatory stress of 0.1 Pa and a set temperature of 10° C. or 25° C.
Comparative Examples C-1 through C-16 and Inventive Examples I-1 through I-15 were prepared by the following method. First, all of the ingredients except for NaCl are mixed for each respective personal care composition using a Speed Mixer (Model No. DAC 400 FVZ by Hauschild) for one minute at 2000 rpm. The one minute interval should be sufficient to achieve a homogenous solution. Next, the solution containing NaCl is added and all ingredients are then remixed. The viscosity and tan delta were then measured for each example as described herein.
The compositions in Tables 1 and 2 depict the percentage of each ingredient, or solution, by weight of the personal care composition. Quantities are expressed as a percentage of the ingredient added including any inactive components contained in the ingredient. As an illustrative example only, a composition containing about 25% of the sodium laureth-3 sulfate ingredient by weight of the composition, indicates a composition containing about 7.0% active sodium laureth-3 sulfate by weight of the composition (25% ingredient by weight of the composition*28% active component of the ingredient=7.0% active sodium laureth-3 sulfate by weight of the composition).
As shown in Table 1, Comparative Examples C-1, C-4 through C-6, and C-11 to C-13 illustrate personal care compositions containing SLS in combination with SLE3S (sodium laureth(3) sulfate), CAPB (cocamidopropyl betaine), and sorbitol. Comparative Examples C-2 and C-7 to C-9 illustrate a personal care composition containing SLE3S and CAPB, but not SLS or a polyol. Comparative Examples C-3, C-10, and C-14 through C-16 illustrate a personal care composition containing SLS, SLE3S, and CAPB, but not a polyol.
Inventive Examples I-1 through I-6, and I-10 through I-12 in Table 2, illustrate personal care compositions containing SLES, CAPB, and sorbitol but not SLS. Inventive Examples I-7 through I-9, and I-13 to I-15 illustrate personal care compositions containing SLES, CAPB and glycerin but not SLS. Inventive Examples I-10 to I-12 illustrate personal care compositions containing SLES, CAPB, and low amounts of sorbitol but not SLS.
Comparing Comparative Examples C-3 to C-4, it appears that the addition of sorbitol alone to personal care compositions containing SLS, SLE3S, and CAPB does not result in stable personal care compositions (i.e. personal care compositions having a tan delta greater than about 0.30 at about 10° C.). Comparing C-2 to C-3, it also appears that the removal of SLS from personal care compositions containing SLE3S and CAPB, but without a polyol, does not result in stable personal care compositions as the resulting composition failed to provide desired rheological properties sought by consumers. For example, C-2 was perceived as too gel-like and difficult to spread on the skin, and therefore not stable.
Finally, comparative Examples C-4 through C-6 illustrate that while increasing the concentration of the viscosity modifier NaCl in personal care compositions containing SLE3S, SLS, CAPB, and sorbitol can enhance the viscosity of the personal care compositions, the inclusion of the viscosity modifier alone does not result in a tan delta greater than 0.30 at about 10° C. for the personal care composition.
Surprisingly, comparing Inventive Examples I-1 to I-6 with Comparative Examples C-2, and C-7 through C-9, illustrate that the inclusion of sorbitol in personal care compositions containing SLE3S and CAPB but not SLS results in personal care compositions with a tan delta greater than 0.30 at about 10° C. The amount of sorbitol by weight of the personal care composition required to stabilize the personal care composition containing SLE3s and CAPB can be under 10% as shown in I-1 through I-6 or even in the range of only about 1.5% to about 4.5% as shown in I-10 through I-12. For example, comparing C-2 to I-2, the addition of approximately 3% sorbitol by weight of the personal care composition to the personal care composition containing SLE3S and CAPB but not SLS, increased the tan delta from about 0.30 at about 10° C. to about 0.36 at about 10° C.
The inclusion of glycerin in personal care compositions containing SLE3S and CAPB but not SLS also results in personal care compositions with a tan delta greater than 0.30 at about 10° C. as seen in Inventive Examples I-7 through I-9 through I-13. Comparing I-7 through I-9 with C-7 through C-9 shows the addition of just about 1% to about 3% glycerin by weight of the personal care composition to the personal care composition containing SLE3S and CAPB but not SLS results in an increase of the tan delta from a range of 0.18 to 0.24 to a range of 0.36 to 0.33.
Comparing I-3 to I-4, it also appears that the viscosity of the stable personal care composition containing SLE3S and CAPB but not SLS can be enhanced by increasing the concentration of the viscosity modifier, NaCl. By comparing I-13 to I-15 with I-7 to I-9, it is also apparent that the viscosity of the stable personal care composition can be enhanced by increasing the viscosity modifier while still retaining a tan delta of 0.30 or more for the personal care composition at 10° C.
The dimensions and values disclosed herein are not to be understood as being strictly limited to the exact numerical values recited. Instead, unless otherwise specified, each such dimension is intended to mean both the recited value and a functionally equivalent range surrounding that value. For example, a dimension disclosed as “40 mm” is intended to mean “about 40 mm.”
All documents cited in the Detailed Description of the Invention are, in relevant part, incorporated herein by reference; the citation of any document is not to be construed as an admission that it is prior art with respect to the present invention. To the extent that any meaning or definition of a term in this document conflicts with any meaning or definition of the same term in a document incorporated by reference, the meaning or definition assigned to that term in this document shall govern.
While particular embodiments of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.
Number | Name | Date | Kind |
---|---|---|---|
5109127 | Sekiguchi | Apr 1992 | A |
5120464 | Kamegai et al. | Jun 1992 | A |
5352386 | Rahman et al. | Oct 1994 | A |
5352387 | Rahman et al. | Oct 1994 | A |
5358656 | Humphreys et al. | Oct 1994 | A |
5385685 | Humphreys et al. | Jan 1995 | A |
5393450 | Shana'a | Feb 1995 | A |
5447652 | Nozaki et al. | Sep 1995 | A |
5529712 | Sano et al. | Jun 1996 | A |
5529768 | Pocalyko et al. | Jun 1996 | A |
5632978 | Moore et al. | May 1997 | A |
5641813 | Franklin et al. | Jun 1997 | A |
5653970 | Vermeer | Aug 1997 | A |
5674511 | Kacher et al. | Oct 1997 | A |
5709852 | Gopalkrishnan et al. | Jan 1998 | A |
5716920 | Glenn, Jr. et al. | Feb 1998 | A |
5734029 | Wulff et al. | Mar 1998 | A |
5854199 | Oshimura et al. | Dec 1998 | A |
5854293 | Glenn, Jr. | Dec 1998 | A |
5858343 | Szymczak | Jan 1999 | A |
5858938 | Glenn, Jr. et al. | Jan 1999 | A |
5863521 | Schaefer et al. | Jan 1999 | A |
5869070 | Dixon et al. | Feb 1999 | A |
5880076 | Vermeer | Mar 1999 | A |
5905062 | Elliott et al. | May 1999 | A |
5919748 | Noguchi et al. | Jul 1999 | A |
5928657 | Simon | Jul 1999 | A |
5929019 | Puvvada et al. | Jul 1999 | A |
5932528 | Glenn, Jr. et al. | Aug 1999 | A |
5942477 | Giret et al. | Aug 1999 | A |
5961992 | Ilardi et al. | Oct 1999 | A |
5965502 | Balzer | Oct 1999 | A |
5968491 | Richardson | Oct 1999 | A |
5968496 | Linares et al. | Oct 1999 | A |
5976520 | Babinski et al. | Nov 1999 | A |
5994280 | Giret et al. | Nov 1999 | A |
6028043 | Glenn, Jr. et al. | Feb 2000 | A |
6033680 | Dixon et al. | Mar 2000 | A |
6057275 | Fair et al. | May 2000 | A |
6107261 | Taylor et al. | Aug 2000 | A |
6121214 | Exner et al. | Sep 2000 | A |
6126954 | Tsaur | Oct 2000 | A |
6194364 | Glenn, Jr. | Feb 2001 | B1 |
6277797 | Glenn, Jr. et al. | Aug 2001 | B1 |
6306805 | Bratescu et al. | Oct 2001 | B1 |
6322799 | Ilardi et al. | Nov 2001 | B1 |
6329331 | Aronson et al. | Dec 2001 | B1 |
6329353 | Dalrymple et al. | Dec 2001 | B1 |
6352689 | Szymczak | Mar 2002 | B1 |
6358493 | Birkel et al. | Mar 2002 | B1 |
6387857 | Chambers et al. | May 2002 | B2 |
6395701 | Connor et al. | May 2002 | B1 |
6407044 | Dixon | Jun 2002 | B2 |
6432896 | Inaba et al. | Aug 2002 | B1 |
6444629 | Elliott et al. | Sep 2002 | B1 |
6475474 | Ricca | Nov 2002 | B1 |
6489274 | LeGrow et al. | Dec 2002 | B1 |
6506713 | Slavtcheff et al. | Jan 2003 | B1 |
6506714 | Soriano et al. | Jan 2003 | B1 |
6525034 | Dalrymple et al. | Feb 2003 | B2 |
6551971 | Inaba et al. | Apr 2003 | B2 |
6566313 | Hohenstein et al. | May 2003 | B1 |
6569439 | Stier | May 2003 | B1 |
6602845 | Connor et al. | Aug 2003 | B2 |
6624126 | Kasuga et al. | Sep 2003 | B1 |
6641825 | Scholz et al. | Nov 2003 | B2 |
6645511 | Aronson et al. | Nov 2003 | B2 |
6660285 | Ricca | Dec 2003 | B2 |
6692754 | Makimoto et al. | Feb 2004 | B1 |
6696067 | Brandt et al. | Feb 2004 | B2 |
6699824 | Dawson et al. | Mar 2004 | B1 |
6706679 | Bergeron et al. | Mar 2004 | B1 |
6716440 | Aronson et al. | Apr 2004 | B2 |
6797683 | Shana'a et al. | Sep 2004 | B2 |
6821942 | Sebillotte-Arnaud et al. | Nov 2004 | B2 |
6849584 | Geary et al. | Feb 2005 | B2 |
6855677 | Matsumoto et al. | Feb 2005 | B1 |
6903057 | Tsaur | Jun 2005 | B1 |
6905694 | Modi | Jun 2005 | B1 |
6906016 | Tsaur | Jun 2005 | B1 |
6916777 | Connor et al. | Jul 2005 | B2 |
6927201 | Hsu et al. | Aug 2005 | B2 |
6949502 | Trinh et al. | Sep 2005 | B2 |
6977238 | Wetzel et al. | Dec 2005 | B1 |
7041627 | Kruse et al. | May 2006 | B2 |
7045491 | Hourigan | May 2006 | B2 |
7138365 | Murayama | Nov 2006 | B2 |
7186674 | Guillou et al. | Mar 2007 | B2 |
7211273 | Hsu | May 2007 | B2 |
7223799 | Sakiguchi et al. | May 2007 | B2 |
7259131 | Fan et al. | Aug 2007 | B2 |
7268106 | Arai | Sep 2007 | B2 |
7279456 | Dufay et al. | Oct 2007 | B2 |
7288616 | Tamareselvy et al. | Oct 2007 | B2 |
7297667 | Potechin et al. | Nov 2007 | B2 |
7297717 | Iwai et al. | Nov 2007 | B2 |
7318929 | Schieferstein et al. | Jan 2008 | B2 |
7332467 | Schneiderman et al. | Feb 2008 | B2 |
7354891 | Arai | Apr 2008 | B2 |
7455848 | Hessefort et al. | Nov 2008 | B2 |
7488841 | Yamawaki et al. | Feb 2009 | B2 |
7504370 | Matsumoto et al. | Mar 2009 | B2 |
7560125 | Ananthapadmanabhan et al. | Jul 2009 | B2 |
7566448 | Becker et al. | Jul 2009 | B2 |
7582592 | Yamamoto et al. | Sep 2009 | B2 |
7649047 | Tamareselvy et al. | Jan 2010 | B2 |
7655744 | Miyanaga | Feb 2010 | B2 |
7670999 | Sebillotte-Arnaud et al. | Mar 2010 | B2 |
7700123 | Sawaki et al. | Apr 2010 | B2 |
7704932 | Evans et al. | Apr 2010 | B2 |
7713520 | Sakuta | May 2010 | B2 |
7737103 | Hloucha et al. | Jun 2010 | B2 |
7776318 | Bissey-Beugras et al. | Aug 2010 | B2 |
7829070 | Nguyen-Kim et al. | Nov 2010 | B2 |
7858567 | Yamamoto et al. | Dec 2010 | B2 |
7863479 | Tropsch et al. | Jan 2011 | B2 |
7879780 | Tsaur | Feb 2011 | B2 |
7902135 | Roso et al. | Mar 2011 | B2 |
7915208 | Roso et al. | Mar 2011 | B2 |
7947260 | Tobita | May 2011 | B2 |
7981851 | Luciow et al. | Jul 2011 | B2 |
8071115 | Sawaki et al. | Dec 2011 | B2 |
8076277 | Luciow et al. | Dec 2011 | B2 |
8105691 | Takeuchi et al. | Jan 2012 | B2 |
8110533 | Tsaur | Feb 2012 | B1 |
8232321 | Ohmori et al. | Jul 2012 | B2 |
8277786 | Yang et al. | Oct 2012 | B2 |
8343520 | Seigneurin et al. | Jan 2013 | B2 |
8361448 | Johnson et al. | Jan 2013 | B2 |
8388939 | Fournial et al. | Mar 2013 | B2 |
8394500 | Beumer et al. | Mar 2013 | B2 |
8404258 | Oguchi et al. | Mar 2013 | B2 |
9463151 | Souda et al. | Oct 2016 | B2 |
20010044393 | Peterson, Jr. et al. | Nov 2001 | A1 |
20010056049 | Aronson et al. | Dec 2001 | A1 |
20020006882 | Loffler et al. | Jan 2002 | A1 |
20020006883 | Dixon | Jan 2002 | A1 |
20020010109 | Chambers et al. | Jan 2002 | A1 |
20020010113 | Kilpatrick-Liverman et al. | Jan 2002 | A1 |
20020051819 | Kuhner et al. | May 2002 | A1 |
20020072483 | Barresi et al. | Jun 2002 | A1 |
20020193266 | Matsumoto et al. | Dec 2002 | A1 |
20030003069 | Carson et al. | Jan 2003 | A1 |
20030064042 | Bergquist et al. | Apr 2003 | A1 |
20030086892 | Klug et al. | May 2003 | A1 |
20030100457 | Ariotto et al. | May 2003 | A1 |
20030175232 | Elliott et al. | Sep 2003 | A1 |
20030211057 | Majeti et al. | Nov 2003 | A1 |
20030236180 | Connor et al. | Dec 2003 | A1 |
20040028711 | Uchida et al. | Feb 2004 | A1 |
20040033913 | Dahms et al. | Feb 2004 | A1 |
20040042986 | Meyer et al. | Mar 2004 | A1 |
20040043045 | Seipel et al. | Mar 2004 | A1 |
20040048758 | Zhang et al. | Mar 2004 | A1 |
20040052754 | West et al. | Mar 2004 | A1 |
20040076654 | Vinson et al. | Apr 2004 | A1 |
20040097472 | West et al. | May 2004 | A1 |
20040115230 | Divone et al. | Jun 2004 | A1 |
20040116539 | Biercevicz et al. | Jun 2004 | A1 |
20040146540 | Ueda et al. | Jul 2004 | A1 |
20040161482 | Kawada et al. | Aug 2004 | A1 |
20040197361 | Oguchi et al. | Oct 2004 | A1 |
20040219125 | Yoneda et al. | Nov 2004 | A1 |
20040234484 | Peffly et al. | Nov 2004 | A1 |
20040235702 | Hawkins | Nov 2004 | A1 |
20040241124 | Lannibois-Drean et al. | Dec 2004 | A1 |
20040266656 | Sakurai | Dec 2004 | A1 |
20050008601 | Ariotto et al. | Jan 2005 | A1 |
20050042261 | Hasenoehrl et al. | Feb 2005 | A1 |
20050096249 | Jonas et al. | May 2005 | A1 |
20050153869 | Connor et al. | Jul 2005 | A1 |
20050154180 | Hessefort et al. | Jul 2005 | A1 |
20050192189 | Wagner et al. | Sep 2005 | A1 |
20050201965 | Kuhlman et al. | Sep 2005 | A1 |
20050227902 | Erazo-Majewicz et al. | Oct 2005 | A1 |
20050256313 | Norenberg et al. | Nov 2005 | A1 |
20050276829 | Stella et al. | Dec 2005 | A1 |
20050277568 | Keenan et al. | Dec 2005 | A1 |
20050296950 | Chrisstoffels et al. | Dec 2005 | |
20060009368 | Norenberg et al. | Jan 2006 | A1 |
20060019847 | Fan et al. | Jan 2006 | A1 |
20060051430 | Arata et al. | Mar 2006 | A1 |
20060062751 | Sato et al. | Mar 2006 | A1 |
20060073110 | Modi | Apr 2006 | A1 |
20060079418 | Wagner et al. | Apr 2006 | A1 |
20060079420 | Wagner et al. | Apr 2006 | A1 |
20060083761 | Yoshimi et al. | Apr 2006 | A1 |
20060088495 | Harichian et al. | Apr 2006 | A1 |
20060089286 | Chakrabarty et al. | Apr 2006 | A1 |
20060093689 | Kawada et al. | May 2006 | A1 |
20060100115 | Sakurai et al. | May 2006 | A1 |
20060115440 | Arata et al. | Jun 2006 | A1 |
20060116305 | Yamato et al. | Jun 2006 | A1 |
20060122322 | Chrisstoffels et al. | Jun 2006 | A1 |
20060134045 | Cao et al. | Jun 2006 | A1 |
20060134047 | Bakeev et al. | Jun 2006 | A1 |
20060142174 | Fukuda et al. | Jun 2006 | A1 |
20060160713 | Sekine et al. | Jul 2006 | A1 |
20060165639 | Gauweiler et al. | Jul 2006 | A1 |
20060183662 | Crotty et al. | Aug 2006 | A1 |
20060189495 | LiBrizzi et al. | Aug 2006 | A1 |
20060228319 | Vona, Jr. et al. | Oct 2006 | A1 |
20070027050 | Crotty et al. | Feb 2007 | A1 |
20070081953 | Dahms | Apr 2007 | A1 |
20070105746 | Dahms | May 2007 | A1 |
20070134176 | Fukui et al. | Jun 2007 | A1 |
20070172441 | Takeda et al. | Jul 2007 | A1 |
20070202071 | Morvan et al. | Aug 2007 | A1 |
20070212320 | Demitz et al. | Sep 2007 | A1 |
20070213243 | Yao et al. | Sep 2007 | A1 |
20070243144 | Takagaki | Oct 2007 | A1 |
20070243241 | Lin et al. | Oct 2007 | A1 |
20070264204 | Noor et al. | Nov 2007 | A1 |
20070274942 | Morvan et al. | Nov 2007 | A1 |
20070286832 | Clapp et al. | Dec 2007 | A1 |
20080031842 | Kuhlman et al. | Feb 2008 | A1 |
20080031845 | Stella et al. | Feb 2008 | A1 |
20080075684 | Barg et al. | Mar 2008 | A1 |
20080108535 | Aubrun-Sonneville | May 2008 | A1 |
20080124295 | Duranton et al. | May 2008 | A1 |
20080169215 | Tanaka et al. | Jul 2008 | A1 |
20080171794 | Yamamoto et al. | Jul 2008 | A1 |
20080193404 | Lange et al. | Aug 2008 | A1 |
20080214776 | Llosas et al. | Sep 2008 | A1 |
20080214850 | Llosas et al. | Sep 2008 | A1 |
20080233061 | Gates et al. | Sep 2008 | A1 |
20080234172 | McGee et al. | Sep 2008 | A1 |
20080255015 | Beilfuss et al. | Oct 2008 | A1 |
20080299054 | Chandar et al. | Dec 2008 | A1 |
20090062406 | Loffler | Mar 2009 | A1 |
20090069522 | Hessefort et al. | Mar 2009 | A1 |
20090081137 | Nguyen Kim et al. | Mar 2009 | A1 |
20090093388 | Yamawaki et al. | Apr 2009 | A1 |
20090197791 | Balastre et al. | Aug 2009 | A1 |
20090214608 | Monin et al. | Aug 2009 | A1 |
20090238769 | Joziak et al. | Sep 2009 | A1 |
20090239776 | Myers | Sep 2009 | A1 |
20090280071 | Kumar et al. | Nov 2009 | A1 |
20090297462 | Hessefort et al. | Dec 2009 | A1 |
20090305929 | Luciow et al. | Dec 2009 | A1 |
20100008884 | Brandt et al. | Jan 2010 | A1 |
20100047300 | Kaupp et al. | Feb 2010 | A1 |
20100061956 | Seigneurin et al. | Mar 2010 | A1 |
20100062961 | Post et al. | Mar 2010 | A1 |
20100075881 | Tsaur | Mar 2010 | A1 |
20100075882 | Ohmori et al. | Mar 2010 | A1 |
20100098646 | Carnali et al. | Apr 2010 | A1 |
20100120645 | Fares et al. | May 2010 | A1 |
20100197543 | Yamato et al. | Aug 2010 | A1 |
20100222305 | West et al. | Sep 2010 | A1 |
20100234260 | Sekine et al. | Sep 2010 | A1 |
20100254928 | Yamazaki et al. | Oct 2010 | A1 |
20100256031 | Wu et al. | Oct 2010 | A1 |
20100261670 | West et al. | Oct 2010 | A1 |
20100311628 | Librizzi et al. | Dec 2010 | A1 |
20100317555 | Araki et al. | Dec 2010 | A1 |
20110033398 | Cauvin et al. | Feb 2011 | A1 |
20110082105 | Fevola et al. | Apr 2011 | A1 |
20110110874 | Tanaka et al. | May 2011 | A1 |
20110150818 | Canfield et al. | Jun 2011 | A1 |
20110152150 | Bernard | Jun 2011 | A1 |
20110155165 | Yamato et al. | Jun 2011 | A1 |
20110230380 | Holzhauer et al. | Sep 2011 | A1 |
20120003338 | Myers | Jan 2012 | A1 |
20120009127 | Dasgupta et al. | Jan 2012 | A1 |
20120009285 | Wei et al. | Jan 2012 | A1 |
20120014885 | Collier et al. | Jan 2012 | A1 |
20120046210 | Patel et al. | Feb 2012 | A1 |
20120070399 | Jegou | Mar 2012 | A1 |
20120071568 | Sugiyama et al. | Mar 2012 | A1 |
20120077880 | Quan et al. | Mar 2012 | A1 |
20120077881 | Quan et al. | Mar 2012 | A1 |
20120101172 | Beutler et al. | Apr 2012 | A1 |
20120114573 | Amalric et al. | May 2012 | A1 |
20120145171 | Ananthapadmanabhan et al. | Jun 2012 | A1 |
20120183590 | Seigneurin et al. | Jul 2012 | A1 |
20120183591 | Dahms | Jul 2012 | A1 |
20120322712 | Yao et al. | Dec 2012 | A1 |
Number | Date | Country |
---|---|---|
101703454 | May 2010 | CN |
19646413 | May 1998 | DE |
19705862 | Jun 1998 | DE |
10007321 | Aug 2001 | DE |
353735 | Feb 1990 | EP |
409005 | Jan 1991 | EP |
473502 | Mar 1992 | EP |
485212 | May 1992 | EP |
493927 | Jul 1992 | EP |
530866 | Mar 1993 | EP |
531684 | Mar 1993 | EP |
559375 | Sep 1993 | EP |
560322 | Sep 1993 | EP |
0 681 832 | Nov 1995 | EP |
706791 | Apr 1996 | EP |
853941 | Jul 1998 | EP |
884380 | Dec 1998 | EP |
1352644 | Oct 2003 | EP |
1422288 | May 2004 | EP |
1661976 | May 2006 | EP |
1672054 | Jun 2006 | EP |
2042216 | Apr 2009 | EP |
2455063 | May 2012 | EP |
2843971 | May 2004 | FR |
2290551 | Jan 1996 | GB |
2297761 | Aug 1996 | GB |
2297975 | Aug 1996 | GB |
05208905 | Aug 1993 | JP |
06016523 | Jan 1994 | JP |
08020525 | Jan 1996 | JP |
2000290148 | Oct 2000 | JP |
2001139456 | May 2001 | JP |
2001140000 | May 2001 | JP |
2002265990 | Sep 2002 | JP |
2004155716 | Jun 2004 | JP |
2005015359 | Jan 2005 | JP |
2006028278 | Feb 2006 | JP |
2006249124 | Sep 2006 | JP |
2006299163 | Nov 2006 | JP |
2009221121 | Oct 2009 | JP |
5183859 | Apr 2013 | JP |
2008035821 | Apr 2008 | KR |
WO9205240 | Apr 1992 | WO |
WO9417783 | Aug 1994 | WO |
WO9418292 | Aug 1994 | WO |
WO9423695 | Oct 1994 | WO |
WO9513355 | May 1995 | WO |
WO9603974 | Feb 1996 | WO |
WO9827938 | Jul 1998 | WO |
WO9924546 | May 1999 | WO |
WO9938489 | Aug 1999 | WO |
WO9938490 | Aug 1999 | WO |
WO9938491 | Aug 1999 | WO |
WO0015180 | Mar 2000 | WO |
WO0115659 | Mar 2001 | WO |
WO0126620 | Apr 2001 | WO |
WO0172262 | Oct 2001 | WO |
WO03084501 | Oct 2003 | WO |
WO2004004678 | Jan 2004 | WO |
WO2004035012 | Apr 2004 | WO |
WO2004064802 | Aug 2004 | WO |
WO2005049782 | Jun 2005 | WO |
WO2006083843 | Aug 2006 | WO |
WO2009103576 | Aug 2009 | WO |
WO2012078159 | Jun 2012 | WO |
WO2012086847 | Jun 2012 | WO |
Entry |
---|
International Search Report and Written Opinion of the International Searching Authority mailed Feb. 5, 2014, PCT/US2013/067159, 17 pages. |
Compositions with Beneficial Properties for Consumers, Ip.Com Journal, Oct. 21, 2008, 35 pages. |
Disinfectant Concentrates as Additives in Various Compositions and Uses, IP.com Journal, Mar. 20, 2008, 68 pages. |
Number | Date | Country | |
---|---|---|---|
20140121268 A1 | May 2014 | US |
Number | Date | Country | |
---|---|---|---|
61719738 | Oct 2012 | US |